Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kadmon announced a new collaboration and license agreement with China’s Jinghua Pharmaceutical to discover, develop and commercialize Kadmon’s fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China.
Subscribe to our email newsletter
Kadmon has also licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market.
Under the terms of the agreement, Kadmon has received a $10m equity investment from Jinghua and has the potential to receive more than $40m upon the achievement of key milestones as well as ten percent royalties on future net sales.
Kadmon president and CEO Harlan Waksal said: "This agreement highlights the value of Kadmon’s scientific work and the depth of our pipeline, including our biologics platform and these important product candidates.
"We look forward to working with Jinghua and are confident in their resources and expertise to bring these monoclonal antibodies to China."
Jinghua general manager Yunzhong Zhou said: "We are pleased to partner with Kadmon to develop these VEGFR2 and PD-L1 monoclonal antibodies, which represent commercially validated targets for the treatment of cancer.
"We believe that combining Kadmon’s platform with Jinghua’s capabilities will help us rapidly develop these assets for the Chinese market."